By Jillian Snider
This is the sixth and final installment in a six-part series examining major federal law enforcement agencies through a research-grounded lens, assessing each agency across the same core categories.
When federal agents dismantle a covert fentanyl lab, when pharmaceutical personnel are charged with unlawful distribution, when investigators trace a methamphetamine pipeline from a Mexican cartel into networks across the U.S., or when the federal government loosens restrictions on the most widely used illegal drug in the country, one agency is at the center of each: the Drug Enforcement Administration (DEA). Yet of the agencies in this series, the DEA is among the least understood as it is often conflated with the broader “war on drugs” rather than recognized for the specific statutory machinery it
operates.
The DEA is the federal government’s lead agency for enforcing the nation’s drug laws, and the youngest of the three Department of Justice (DOJ) agencies examined in this series. But its defining feature is that it does not merely enforce the drug laws, it also helps determine which substances are controlled, and how tightly,
through its authority over the federal drug-scheduling system. Those scheduling decisions, in turn, help define what counts as a federal drug crime in the first place. It is that combination of powers, enforcing the drug laws while also helping to write them, that has drawn the DEA into one of the most consequential drug-policy debates in a generation: the rescheduling of marijuana, an issue that has reached a turning point in 2026.